I. MODIFIED AGREEMENTS | |||
Biotech Co.* |
Pharma Co. |
Change from original |
Terms/Details (Date) |
|
| |||
AEterna |
Solvay Pharmaceuticals BV (Belgium |
AEterna regained rights to cetrorelix for benign prostate hyperplasia except in Japan; late-stage trials are planned |
Solvay is continuing development of the LHRH antagonist in gynecological indications; no payment was made in the restructuring of the January 2004 deal (1/30) |
Biomira Inc. |
Merck KGaA (Germany) |
Merck will takes over administrative and financial responsibility for the liposome cancer vaccine L-BLP25 |
Biomira's co-promotion interest in U.S. sales will be converted to a royalty structure; Biomira retains manufacturing rights, and rights in Canada; milestone terms remain the same (1/26) |
Celera |
Abbott Laboratories |
They restructured deal focused on development of molecular diagnostics |
They will continue working together in most areas in a profit-sharing arrangement but can work individually in certain other areas (1/9) |
Cephalon Inc. |
Barr Laboratories Inc. |
They settled patent litigation related to Cephalon's Provigil and Actiq products |
Barr got nonexclusive rights to market a generic version of Provigil in the U.S. starting in October 2011 and to market a generic version of Actiq starting in December 2006; Cephalon would get royalties (2/1) |
Cephalon Inc. |
Mylan |
They settled a patent |
Mylan got a nonexclusive, royalty-bearing right to market a generic version of Provigil starting in October 2011 (1/10) |
Oscient |
Vicuron Pharmaceuticals Inc. (unit of Pfizer Inc.) |
Oscient, which had rights to Ramoplanin in the U.S. and Canada, acquired worldwide rights and assumed full control of the product |
Pfizer gets an up-front payment and potential milestone and royalty payments; the drug is nearing Phase III trials for treating Clostridium difficile-associated disease (2/8) |
Progenics |
UR Labs Inc. |
Progenics acquired a substantial portion of the royalty and milestone rights to methylnaltrexone (MNTX) |
Progenics initially licensed rights to the drug from UR Labs in 2001; UR Labs received 686,000 Progenics shares and $2.6M in cash (12/23) |
II. TERMINATED AGREEMENTS | |||
Enzon |
Fresenius Biotech GmbH (division of Fresenius AG; Germany) |
Enzon returned rights to ATG-Fresenius S, a polyclonal antibody preparation designed for suppressing T lymphocytes |
Enzon licensed North American rights to the transplant rejection product in June 2003; Enzon said ending the deal was due to a redirected focus at the company (1/6) |
Epigenomics |
Roche Diagnostics (Switzerland) |
Roche is returning rights to a test for Tamoxifen treatment response and breast cancer molecular classification |
Epigenomics plans to develop the test itself; they remain partnered on screening products for colon, prostate and breast cancers (1/30) |
Ligand |
Organon USA Inc. |
They terminated co-promotion deal covering the pain drug Avinza |
Ligand regained rights to the product and will continue paying royalties to Organon; they also resolved a dispute concerning prior co-promotion fees (1/17) |
NeuroSearch |
Boehringer Ingelheim GmbH (Germany) |
BI terminated deal covering the development of tesofensine (NS2330) |
The move followed unsuccessful Phase II trials in 2005 in Alzheimer's and Parkinson's diseases; NeuroSearch plans continued development with a new partner (1/25) |
NitroMed Inc. |
Boston Scientific Corp. |
A research program on nitric oxide-enhancing technology came to a close Dec. 31 |
The technology was being studied with restenosis in balloon angioplasty; NitroMed intends to continue to explore using the technology in medical devices (12/29) |
Santarus Inc. |
TAP Pharmaceutical Products Inc. |
TAP exercised its right to terminate June 2002 sublicense agreement |
TAP had North American rights to use Santarus' immediate- release proton pump inhibitor technology with lansoprazole, a PPI; Santarus now has worldwide rights to the technology (1/9) |
SciGen Ltd. |
Ferring AG |
Ferring is terminating deal under which it supplied human growth hormone in Singapore and South Korea |
SciGen said it has taken measures to ensure it has adequate supplies for those markets; they are discussing continuation of the collaboration (2/3) |
|
| |||
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; PK = Pink Sheets. | |||
